A meta-analysis of clinical studies revealed that treating patients who have type 2 diabetes mellitus and are obese with GLP-1 RAs did not increase the risk of breast cancers, acute pancreatitis, pancreatic cancer, or overall tumor neoplasia. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.